The elimination of caffeine was investigated in a 1860 g, 31 week gestation neonate, following the accidental administration of a 160 mg.kg -1 dose. The first serum concentration measured was 217.5 mg.l -1 at 36.5 h after dosing. Fitting of time-concentration data was performed using non-linear regression with MKMODEL. A first order elimination model was superior to a mixed order model. Parameter estimates were: clearance 0.01 l.h -1 , volume of distribution 1.17 litres, elimination half-life 81 h. Toxic manifestations included hypertonia, sweating, tachycardia, cardiac failure, pulmonary oedema and metabolic disturbances (metabolic acidosis, hyperglycaemia and creatine kinase elevation). An unusual feature of this infant's illness course was gastric dilatation. These signs resolved by day 7 at a serum concentration of 60-70 mg.l -1 .
Caffeine is a central stimulant used for the management of apnoea in premature neonates 1 . Theophylline is also used for this indication and acts as a prodrug for caffeine in the neonate 2 . The cytochrome P-450 (CYP1A2) mediating the N-demethylation elimination pathway of theophylline is almost absent in premature neonates. Consequently, about 50% of a theophylline dose is excreted in the urine and the remainder undergoes Nmethylation to caffeine and C-8 hydroxylation to 1,3dimethyluric acid 3 . Steady state concentrations of caffeine average about 30% those of theophylline 4 . Caffeine has a more predictable effect than theophylline, a decreased propensity for toxicity, and the long terminal elimination half-life in the neonate allows dosing either once a day or once every two days.
We report the complications, management and kinetics of an accidental overdose of caffeine in a premature neonate.
CASE HISTORY
The neonate was an 1860 g female delivered vaginally at 31 weeks gestation to a 24 year old Pacific Island, gravida 2 para 1 woman at National Women's Hospital, Auckland. Apgars were 9 and 10 at 1 and 5 minutes respectively. Within six hours the neonate developed episodes of apnoea with pulse oximetry recordings dropping to below 70% saturation. These episodes were managed with oxygen by nasal prong continuous positive airway pressure (CPAP) and intravenous caffeine. A dose of 25 mg.kg -1 (total dose 46 mg) was prescribed, but a tenfold dosing administration error occurred and an infusion of 460 mg caffeine was set up to run over an hour. The intravenous site used to administer the caffeine extravasated into the tissues during the infusion, causing an area of necrosis on the dorsum of the hand over the subsequent 24 hours. An estimated 300 mg caffeine was delivered over a 40 minute period.
The neonate rapidly developed signs consistent with caffeine toxicity: irritability, jitteriness, hypertonia, sweating and tachycardia (180-200 bpm). An electrocardiogram showed ST depression in the mid-precordial leads with increased right ventricular dominance and axis deviation. Respiratory function deteriorated due to a combination of respiratory distress syndrome (RDS) and cardiac failure and the neonate was admitted to the neonatal intensive care unit for mechanical ventilation. Chest X-rays over the subsequent 48 hours showed an increased cardiothoracic ratio and pulmonary changes consistent with pulmonary oedema. Copious fresh blood stained pulmonary secretions on day 3 causing obstruction of the lumen were managed by frequent endotracheal tube changes. Following a brief but unsuccessful trial of esmolol (50 µg.kg -1 .min -1 graded up to 100 µg.kg -1 .min -1 ) on day 1 to control the tachycardia, cardiac failure was managed with frusemide (1 mg.kg -1 .day -1 ) and positive end expiratory pressure (PEEP) 7 cm H 2 O. As respiratory function improved, the neonate was extubated on day 5 and was managed with naso-pharyngeal CPAP until day 7.
Metabolic derangement over the initial four days included a metabolic acidosis (Day 1: pH 7.29, PO 2 5.2 kPa, PCO 2 4.7 kPa, HCO 3 12 mmol.l -1 , base excess -13 mmol.l -1 ); this was managed with an infusion of bicarbonate 3 mmol.kg -1 .day -1 . A five-day infusion of insulin (0.05-0.1 U.kg -1 .h -1 , titrated to achieve a plasma glucose of 3.5-7 mmol.l -1 ) was used to treat hyperglycaemia (plasma glucose 23.2 mmol.l -1 at 16 hours after caffeine). Creatine kinase was 907 U.l -1 (N 40-240 U.l -1 ) on day 4 and was attributed to rhabdomyolysis.
The neonate was given a loading dose of phenobarbitone (20 mg.kg -1 ) and maintained with 5 mg.kg -1 .day -1 until day 7 in an effort to increase hepatic clearance by enzyme induction.
An unusual feature of this child's illness course was gastric dilatation ( Figure 1 ) and intolerance to nasogastric milk feeding. Total parenteral nutrition was required until day 7. Gastric dilatation decreased slowly and by day 4 there was evidence of air distally in non-dilated bowel. An ultrasound scan showed no evidence of pyloric stenosis or any peri-pyloric collection which may have accounted for this phenomenon. Gastric dilatation completely resolved by day 7 and the neonate made an uneventful recovery without any sequelae evident at the six month follow-up.
Caffeine Assay
Serum caffeine was measured using a homogeneous enzyme multiplied immunoassay technique (Emit, Behring Diagnostics, San Jose, CA, U.S.A.) and a centrifugal analyser (COBAS BIO, Hoffman-LaRoche, Basle, Switzerland). The assay as designed by the manufacturer has a measuring range of 1-30 mg.l -1 and in our hands a coefficient of variation between assays of 15% at a concentration of 12 mg.l -1 . All patient specimens were diluted with an equal volume of blank serum before assay to give an effective measuring range of 2-60 mg.l -1 , with very high concentrations requiring even greater dilution.
Pharmacokinetic Modelling
Serum caffeine concentrations were measured over a 250 hour period after administration. A onecompartment model with first order elimination was used to estimate clearance (CL) and volume of distribution (Vd) using non-linear regression with MKMODEL 5 . The first order model for rate of change of concentration at time t, (dC(t)/dt) was: dC(t)/dt=(Dose/TK0-CL*C)/Vd mg.l -1 .h -1 C is the serum caffeine concentration (mg.l -1 ), CL is the total body clearance (l.h -1 ), Vd is the volume of distribution (l), Dose/TK0 is the zero order administration rate (TK0, time of infusion, 40 min). A dose of 300 mg was used.
A mixed order elimination model was also fitted to the data in order to determine which of the two models was the better fit. dC(t)/dt=(Dose/TK0-Vmax/(Km+C)*C)/Vd mg.l -1 .h -1 Vmax is the maximum rate of metabolism and Km the Michaelis-Menten constant. Residual error was described using a proportional variance model.
The parameter values for Vmax and clearance were standardized for a body weight of 70 kg using an allometric power model 6 .
P i =P std *(W i /W std ) 3, 4 where P i is the parameter in the ith individual, W i is the weight in the ith individual and P std is the parameter in an individual with a weight W std . Peters 7 has reviewed the evidence that for functional properties of the body such as metabolic rate, a typical power value is 3/4. This parameter is the same for homeotherms, poikilotherms and unicellular organisms. Clearance estimates reported in the literature were reviewed using this allometric 3/4 power model. When applied to physiological volumes such as blood, lung or drug distribution volumes the power parameter is 1 8 .
The Schwartz criterion 9 , a measure of the likelihood of fit which accounts for the number of parameters and observations, was used to determine the preferred model.
RESULTS
The model-generated time-concentration profile for the first order elimination model is shown graphically in Figure 2 . Parameter estimates for the first order and mixed order models are shown in Tables 1 and 2. The first order elimination model resulted in a better fit than the mixed order model (Schwarz criterion -39.5 vs -45.5). The elimination half-life was 81h.
Literature clearance estimates, originally scaled per kg, were standardized to a 70 kg human using the allometric 3/4 power model and the parameters estimated described herein (Table 3 ). From this model the clearance of caffeine in infants seems to approach that of adults by three months of age.
DISCUSSION
Elimination of caffeine after an accidental overdose in this premature infant followed a first order process. Parameter estimates for clearance and volume of distribution were similar to those described by others 10, 11 in studies of population pharmacokinetics in premature neonates maintained on caffeine for the management of apnoea. Hepatic metabolism of caffeine in newborn premature infants is almost absent 10 term neonates, caffeine accounts for more than 85% of the identifiable products in urine 12 . The addition of phenobarbitone in an effort to induce hepatic enzyme synthesis had little effect because the vast majority of caffeine is cleared by the kidney. Phenobarbitone induces activity in the P450 3A rather than the P450 1A cytochrome subgroup 13 and induction can be detected within 6 or 7 days 14 . It is unlikely to have an immediate clinical effect on caffeine elimination in premature neonates. This lack of mixed order elimination kinetics contrasts with both theophylline metabolism in infants 15 and caffeine metabolism in adults 16, 17 . The use of frusemide to manage cardiac failure may have increased renal elimination of caffeine in this individual, but parameter estimates were similar to those determined by population analysis techniques 10, 11 .
Inappropriate size models for young children have led to misconceptions such as the enhanced capacity of children to metabolize drugs 18 . When weight is standardized and disentangled from age, developmental changes can be understood more clearly. The allometric 3/4 power model assists in the ability to predict the parameters in a given species, including humans, based on values found for other mammalian species 19 . Clearance is a non-linear function of body weight. The linear per kilogram model is inaccurate in the lower age ranges. In humans, underprediction of clearance of more than 10% occurs at body weights less than 47 kg 6 . This error increases as size decreases and approaches 50% for a term neonate. This gross underprediction in the very young is not always seen clinically because of immaturity of hepatic and renal systems. Caffeine clearance in the very young can be demonstrated to approach adult rates by three months of age when an allometric model is used. Caffeine is reported to be the predominant urinary component for the first three months, but its percentage decreases gradually to the adult value of less than 2% by the age of 7 to 9 months 12 . The maturation of cytochrome P450 CYP1A2 to adult levels occurs by a postnatal age 120 days 20 . The increase in clearance of caffeine by three months is probably attributable to maturing renal function and hepatic P450 cytochrome activity.
A serum concentration of 60 to 70 mg.l -1 correlated with resolution of manifestations of toxicity on days 6 and 7. The problems with hyperglycaemia, cardiac failure and gastric dilatation had improved. These toxic manifestations are expected with an overdose of the xanthine derivatives which are inhibitors of adenosine, a cardiac and central nervous system activity suppressant. Cardiovascular collapse after caffeine overdose is described in adults 21 . Although this neonate developed cardiac failure, cardiovascular collapse did not occur, probably because of the ability of neonates to tolerate tachycardia better than adults and consequently have a decreased propensity to cardiac ischaemia. Survival after such a large overdose has been described in both children 22 and adults 23 , but these patients were managed with emergency charcoal haemoperfusion in order to lower serum caffeine concentrations. The gross and persistent gastric distension observed in this child has not been described previously and may have been due to the ability of the xanthine derivatives to relax smooth muscle 24 . Rhabdomyolysis has been described in an adult without renal failure following a suicide ingestion of tablets containing paracetamol, phenazone and caffeine 25 , but has not been described secondary to caffeine alone.
Although caffeine has been known to be efficacious in the treatment of apnoea in the low birthweight infant for over 20 years 26 , it has only recently gained ascendancy over theophylline use. This case report illustrates the hazards which may occur when any new drug is introduced into a busy neonatal intensive care unit. The commonest drug administration error in infants is one of dose 27 . The commonest hospital site is the intensive care unit 28 . Drug errors are a consequence of system error and preventive strategies are possible through system analysis. The burden of drug administration falls heavily on nurses. Their role involves accurate and appropriate drug administration, assessment of therapeutic response as well as prevention, detection and amelioration of adverse effects 29 . Standard nursing education teaches the five rights of drug administration: right drug, right dose, right patient, right route and right time. Goals of zero drug error rate should be aggressively sought with systems in place that seek to eliminate the effects of inevitable human error 30 .
